October 21, 2016
Janssen Pharmaceutical announced on October 20 that it has submitted a marketing authorization application in Japan for the human anti-IL-6 monoclonal antibody sirukumab (recombinant) for the treatment of rheumatoid arthritis (RA) in adults. The application was based on data from...read more